NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis

Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XENE

$59.75

−$0.65 (−1.08%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XENE with… →

XENE Key Statistics

As of Sep 4, 2026
Trading
Open
$60.02
Previous Close
$60.40
Day's Range
59.43–60.57
52-Week Range
35.60–72.66
Volume
459.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$5.79B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.74
Financials (FY)
Revenue (FY)
$7.50M
Net Income (FY)
−$345.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
96.84M
1-Year Return
+54.63%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
1.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XENE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+33.31%
2025+14.34%
2024−14.89%
2023+16.81%
2022+26.22%
2021+103.12%
2020+17.32%
2019+107.77%
2018+123.36%
2017−63.31%
2016 (partial year)+1.85%

As of September 4, 2026.

XENE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.50M−$345.91M−4612.1%
2024$0.00−$234.33M—
2023$0.00−$182.39M—
2022$9.43M−$125.37M−1328.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.50M—−$373.07M−$345.91M−4612.1%
2024$0.00—−$279.30M−$234.33M—
2023$0.00—−$214.05M−$182.39M—
2022$9.43M—−$129.14M−$125.37M−1328.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XENE Valuation vs Biotechnology Median

Median of 656 stocks
MetricXENEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xenon Pharmaceuticals Inc. (XENE) carries a market capitalisation of $5.79B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 358 employees.

XENE last closed at $59.75 on September 4, 2026. That is −$0.65 (−1.08%) against the previous close. The 52-week range on file runs from $35.60 to $72.66. The latest close sits 67.84% above that 52-week low.

Financial Health

In fiscal 2025, Xenon Pharmaceuticals Inc. reported revenue of $7.50M. The same year closed with a net loss of $345.91M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.74.

Across the 4 fiscal years on file, revenue moves from $9.43M in 2022 to $7.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.62. Annualized volatility over the trailing 10 years is 66.27%. Over the trailing twelve months the price has returned +54.63%. Across 10 years the annualized return works out at +22.27%.

Growth & Income

No dividend is on file for XENE.

2026 is still running; the price is +33.31% year to date. The strongest complete calendar year on file is 2018 at +123.36%; the weakest is 2017 at −63.31%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Xenon Pharmaceuticals Inc. (XENE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xenon Pharmaceuticals Inc. XENE $5.79B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Xenon Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Visit website →